LASA Supergenerics Declares Non-Applicability of Large Entities Framework Under SEBI Guidelines

1 min read     Updated on 16 Apr 2026, 05:05 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

LASA Supergenerics Limited has declared to BSE and NSE that it does not fall under the Large Corporate category as per SEBI Circular dated November 26, 2018. The declaration, submitted on April 16, 2026, confirms the company's exemption from the Large Entities framework for debt securities issuance, ensuring compliance with regulatory transparency requirements.

powered bylight_fuzz_icon
37884914

*this image is generated using AI for illustrative purposes only.

LASA Supergenerics Limited has officially declared to stock exchanges that it falls outside the purview of the Large Corporate category as per SEBI's regulatory framework. The declaration was made pursuant to SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

Regulatory Compliance Declaration

The company submitted its declaration to both BSE Limited and National Stock Exchange of India Limited on April 16, 2026. The communication specifically addressed the non-applicability of the Large Entities framework for fund raising through debt securities issuance.

Parameter Details
SEBI Circular Reference SEBI/HO/DDHS/CIR/P/2018/144
Circular Date November 26, 2018
Declaration Date April 16, 2026
BSE Code 540702
NSE Code LASA

Framework Exemption Status

LASA Supergenerics Limited confirmed that it does not meet the criteria to be classified as a Large Corporate entity under the SEBI framework. This exemption means the company is not subject to the specific compliance requirements and guidelines established for large entities when raising funds through debt securities.

Corporate Communication

The declaration was signed by Ganesh Potdar, Director of the company, with DIN 11455401. The document was digitally signed and submitted to the corporate services departments of both stock exchanges as part of the company's regulatory compliance obligations.

This declaration ensures that LASA Supergenerics Limited maintains transparency with regulatory authorities and stock exchanges regarding its corporate classification status under current SEBI guidelines.

Historical Stock Returns for Lasa Supergenerics

1 Day5 Days1 Month6 Months1 Year5 Years
+1.04%+14.57%+22.44%-13.56%-50.82%-86.19%

What are LASA Supergenerics' upcoming debt fundraising plans now that it's exempt from Large Corporate compliance requirements?

How might this regulatory exemption impact the company's cost of capital and financing strategy compared to larger pharmaceutical competitors?

Will LASA Supergenerics need to reassess its classification status as the company grows, and what revenue thresholds would trigger Large Corporate categorization?

Lasa Supergenerics Board Approves Q3FY26 Results Showing Rs 255.47 Lakh Loss

2 min read     Updated on 14 Feb 2026, 03:33 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Lasa Supergenerics Limited's Board approved Q3FY26 financial results showing continued losses due to operational suspension following a May 2025 fire incident. The company reported a net loss of Rs 255.47 lakh with dramatically reduced revenue, while exploring alternative manufacturing arrangements subject to regulatory approvals.

powered bylight_fuzz_icon
32524757

*this image is generated using AI for illustrative purposes only.

Lasa Supergenerics Limited's Board of Directors approved the company's unaudited financial results for Q3FY26 on February 13, 2026, revealing continued operational and financial challenges. The board meeting, which commenced at 2:00 PM and concluded at 3:15 PM, approved results showing a net loss of Rs 255.47 lakh for the quarter ended December 31, 2025.

Financial Performance Overview

The company's financial performance reflects the severe impact of operational disruptions on its business operations. Revenue from operations declined dramatically to Rs 219.93 lakh in Q3FY26 compared to Rs 3,307.99 lakh in Q3FY25, representing a substantial year-on-year decrease.

Financial Metric: Q3FY26 Q3FY25 Change
Revenue from Operations: Rs 219.93 lakh Rs 3,307.99 lakh Significant decline
Total Income: Rs 221.72 lakh Rs 3,374.87 lakh Sharp reduction
Net Profit/(Loss): Rs (255.47) lakh Rs 549.39 lakh Loss reported
Basic EPS: Rs (0.51) Rs 1.10 Negative earnings

Board Meeting and Regulatory Compliance

The Board of Directors meeting held on February 13, 2026, considered and approved the unaudited financial results along with the Limited Review Report from the statutory auditor. The company has submitted integrated filing for the quarter ended December 31, 2025, pursuant to SEBI regulations and BSE/NSE circulars.

Chairman and Managing Director Omkar Herlekar digitally signed the regulatory filings, confirming compliance with SEBI listing obligations and disclosure requirements. The financial results are available on the company's website at www.lasalabs.com and stock exchange websites.

Impact of Fire Incident

The company's operational challenges stem from a major fire incident that occurred on May 18, 2025, at its main manufacturing facility located at Plot No. C-4 in Lote Parshuram Industrial area, Ratnagiri, Maharashtra. This incident has had cascading effects on the company's entire production ecosystem.

The fire caused extensive damage to multiple aspects of the facility, including inventories, property, plant and equipment, and office areas. As this unit served as the central hub for primary production activities, the damage resulted in a complete halt of all production processes.

Exceptional Items and Losses

The fire incident resulted in substantial uninsured losses that have been recognized as exceptional items in the financial statements. The total exceptional loss amounts to Rs 2,057.47 lakh for the nine-month period.

Loss Category: Amount (Rs in Lakh)
Inventories: 1,273.62
Property, Plant & Equipment (provisional): 700.00
Other Expenses: 83.85

The affected assets were not covered by insurance, amplifying the financial impact on the company. The management has duly informed stock exchanges, the Factory Inspector, and the Office of the Labor Commissioner regarding the suspension of operations.

Auditor's Review and Going Concern

Statutory auditors Gupta Rustagi & Co. provided a limited review report highlighting the company's inability to commence manufacturing activities due to pending statutory clearances and operational constraints. The auditors noted that management is actively exploring alternative options including contract manufacturing arrangements and facility leasing, subject to regulatory approvals.

Additional challenges include dormant bank accounts with a book balance of Rs 7.99 lakh and fixed deposits worth Rs 31.46 lakh as of December 31, 2025, for which confirmations could not be obtained due to dormant status.

Historical Stock Returns for Lasa Supergenerics

1 Day5 Days1 Month6 Months1 Year5 Years
+1.04%+14.57%+22.44%-13.56%-50.82%-86.19%

More News on Lasa Supergenerics

1 Year Returns:-50.82%